DSGN vs FULC vs SRPT vs IMVT

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 15. 6% revenue growth year-over-year, versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). Analysts rate Design Therapeutics, Inc. (DSGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus DSGN's -66. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immunovant, Inc.

(IMVT) is the lower-risk stock at 1. 37β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 47% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 15. 6% versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). On earnings-per-share growth, the picture is similar: Design Therapeutics, Inc. grew EPS -38. 6% year-over-year, compared to -637. 5% for Fulcrum Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Design Therapeutics, Inc.

(DSGN) is the more profitable company, earning 0. 0% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DSGN leads at 0. 0% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FULC: 200.

4% to $20. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immunovant, Inc.

(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DSGN is a small-cap quality compounder stock; FULC is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.